加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$5.46
−US$0.47 · -7.93%
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
前收盘价
US$5.46
−US$0.47 · -7.93%
盘中时间采用ET。市场数据可能有所延迟。
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
日内区间
当前US$5.46
52周区间
当前US$5.46
盘中时间采用ET。市场数据可能有所延迟。
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
日内区间
当前US$5.46
52周区间
当前US$5.46
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 185万 USD | 319.03万 USD | 500.37万 USD | 655.42万 USD | 548.25万 USD |
| 销售、一般及管理费用 | 391.31万 USD | 762.69万 USD | 551.7万 USD | 660.34万 USD | 601.58万 USD |
| 营业费用 | 576.31万 USD | 1081.71万 USD | 1052.07万 USD | 1315.76万 USD | 1149.83万 USD |
| 利息支出 | — | — | — | 2.15万 USD | — |
| 折旧和摊销 | 15.73万 USD | 20.62万 USD | 27.55万 USD | 23.43万 USD | 22.44万 USD |
| 营业利润 | −576.31万 USD | −1081.71万 USD | −1052.07万 USD | −1315.76万 USD | −1149.83万 USD |
| 净利润 | −702.74万 USD | −1150.79万 USD | −1006.03万 USD | −1317.91万 USD | −1123.13万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
